MCID: MYS005
MIFTS: 56

Myositis

Categories: Muscle diseases, Neuronal diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Myositis

Summaries for Myositis

MedlinePlus : 41 myositis means inflammation of the muscles that you use to move your body. an injury, infection, or autoimmune disease can cause it. two specific kinds are polymyositis and dermatomyositis. polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. dermatomyositis causes muscle weakness, plus a skin rash. other symptoms of myositis may include fatigue after walking or standing tripping or falling trouble swallowing or breathing doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. there is no cure for these diseases, but you can treat the symptoms. polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. nih: national institute of neurological disorders and stroke

MalaCards based summary : Myositis, also known as inflammatory disorder of muscle, is related to glomerulonephritis and laryngitis, and has symptoms including proximal muscle weakness, back pain and muscle cramp. An important gene associated with Myositis is IFIH1 (Interferon Induced With Helicase C Domain 1), and among its related pathways/superpathways are Neuroscience and tRNA Aminoacylation. The drugs Simvastatin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and skin, and related phenotypes are Decreased viability and behavior/neurological

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

Wikipedia : 72 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 360)
id Related Disease Score Top Affiliating Genes
1 glomerulonephritis 29.9 DMD MB PIK3C2A
2 laryngitis 29.9 NCAM1 PIK3C2A TTN
3 pick disease 29.7 APP BACE1 MAPT
4 congenital myopathy 29.6 DMD TTN
5 lyme disease 28.9 CAPN3 DMD DYSF GNE PIK3C2A TTN
6 inclusion body myositis 12.4
7 myositis ossificans 12.2
8 myositis fibrosa 12.0
9 fibrodysplasia ossificans progressiva 12.0
10 focal myositis 12.0
11 bacterial myositis 11.9
12 viral myositis 11.9
13 idiopathic eosinophilic myositis 11.9
14 infective myositis 11.9
15 fungal myositis 11.9
16 overlap myositis 11.9
17 granulomatous myositis 11.9
18 juvenile overlap myositis 11.8
19 pyomyositis 11.8
20 idiopathic inflammatory myopathy 11.7
21 dermatomyositis 11.6
22 myopathy 11.2
23 polymyositis 11.2
24 antisynthetase syndrome 11.1
25 necrotizing autoimmune myopathy 10.8
26 salih myopathy 10.8 CAPN3 TTN
27 adrenal carcinoma 10.8 DYSF PIK3C2A
28 xanthinuria, type ii 10.7
29 muscle disorders 10.7
30 welander distal myopathy, swedish type 10.7
31 foot drop 10.7
32 lopes gorlin syndrome 10.7 DMD DYSF
33 multiple endocrine neoplasia 10.7 CAPN3 DMD
34 osseous heteroplasia, progressive 10.7
35 childhood type dermatomyositis 10.7
36 epidemic pleurodynia 10.7
37 orbital plasma cell granuloma 10.7
38 osteogenesis imperfecta with opalescent teeth, blue sclerae and wormian bones but without fractures 10.7 CAPN3 DYSF TTN
39 hypertrophic cardiomyopathy 21 10.7 CAPN3 DYSF
40 anonychia congenita 10.7 CAPN3 DMD
41 charcot-marie-tooth disease, type 2b2 10.7 CAPN3 DYSF TTN
42 visual snow syndrome 10.6 MB PIK3C2A
43 personality disorder 10.6 APP BACE1 MAPT
44 miyoshi muscular dystrophy 1 10.6 CAPN3 CHKB DYSF
45 endometrial type cervical adenomyoma 10.6 MB PIK3C2A
46 acetyl-coa carboxylase deficiency 10.6 CAPN3 DYSF
47 aortic arch anomaly - peculiar facies - intellectual disability 10.6 HARS TARS
48 inferior myocardial infarction 10.5 MAPT MB PIK3C2A
49 pulmonary hypertension, primary, 2 10.5 CAPN3 DMD DYSF
50 intracranial structure hemangioma 10.5 APP MAPT

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Human phenotypes related to Myositis:

32
id Description HPO Frequency HPO Source Accession
1 proximal muscle weakness 32 HP:0003701
2 myositis 32 HP:0100614

UMLS symptoms related to Myositis:


back pain, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, myalgia

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.66 PIK3C2A
2 Decreased viability GR00221-A-1 9.66 GNE PIK3C2A CHKB
3 Decreased viability GR00221-A-2 9.66 PIK3C2A TTN CHKB
4 Decreased viability GR00221-A-3 9.66 GNE CHKB
5 Decreased viability GR00221-A-4 9.66 DYSF GNE PIK3C2A TTN CHKB
6 Decreased viability GR00240-S-1 9.66 PIK3C2A
7 Decreased viability GR00301-A 9.66 CHKB DYSF
8 Decreased viability GR00342-S-1 9.66 PIK3C2A TTN
9 Decreased viability GR00342-S-2 9.66 PIK3C2A
10 Decreased viability GR00342-S-3 9.66 PIK3C2A TTN
11 Decreased hepcidin::fluc mRNA expression GR00253-A 9.61 AARS APP BACE1 DMD DYSF MSTN

MGI Mouse Phenotypes related to Myositis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 BACE1 CHKB DMD DYSF GNE MAPT
2 cellular MP:0005384 10.15 IFIH1 MAPT MB MSTN NCAM1 PIK3C2A
3 growth/size/body region MP:0005378 10.13 APP BACE1 BACE2 CAPN3 DMD GNE
4 homeostasis/metabolism MP:0005376 10.07 GNE IFIH1 MAPT MB MSTN PIK3C2A
5 cardiovascular system MP:0005385 10.06 AARS CAPN3 DMD GNE MAPT MB
6 mortality/aging MP:0010768 10 AARS APP BACE1 BACE2 DMD FBL
7 muscle MP:0005369 9.73 AARS APP BACE1 CAPN3 CHKB DMD
8 no phenotypic analysis MP:0003012 9.17 APP BACE1 CAPN3 DMD DYSF MAPT

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
2
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
5
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
6
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
7
Liraglutide Approved Phase 4 204656-20-2 44147092
8 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
9
Angiotensin II Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
10
Pirfenidone Investigational Phase 4 53179-13-8 40632
11 Anticholesteremic Agents Phase 4,Phase 2
12 Antimetabolites Phase 4,Phase 3,Phase 2
13 Calcium, Dietary Phase 4,Phase 3,Phase 2,Early Phase 1
14 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3
15 Hypolipidemic Agents Phase 4,Phase 2
16 Lipid Regulating Agents Phase 4,Phase 2
17 Rosuvastatin Calcium Phase 4 147098-20-2
18 Anti-HIV Agents Phase 4
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Anti-Retroviral Agents Phase 4
21 Antiviral Agents Phase 4,Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
23 Reverse Transcriptase Inhibitors Phase 4
24
Tenofovir Phase 4 147127-20-6 464205
25 Vaccines Phase 4
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Angiotensin II Type 1 Receptor Blockers Phase 4
34 Angiotensin Receptor Antagonists Phase 4
35 Angiotensinogen Phase 4
36 Antihypertensive Agents Phase 4
37 HIV Protease Inhibitors Phase 4
38
Olmesartan medoxomil Phase 4 144689-63-4 130881
39
protease inhibitors Phase 4
40 Serine Proteinase Inhibitors Phase 4
41 Vasoconstrictor Agents Phase 4
42 Micronutrients Phase 4,Phase 2,Phase 3
43 Trace Elements Phase 4,Phase 2,Phase 3
44 Ubiquinone Phase 4,Phase 2,Phase 3
45 Vitamins Phase 4,Phase 2,Phase 3
46 Adrenocorticotropic Hormone Phase 4,Phase 2
47 beta-endorphin Phase 4,Phase 2
48 Melanocyte-Stimulating Hormones Phase 4,Phase 2
49 insulin Phase 4,Phase 1
50 Insulin, Globin Zinc Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 159)

id Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
5 Angiotensin II Blockade and Inflammation in Obesity Completed NCT01684748 Phase 4 Olmesartan medoxomil
6 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Completed NCT02255682 Phase 4 Simvastatin
7 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
8 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
9 Living With Statins - Interventional Exercise Study Recruiting NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
10 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
11 The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans Active, not recruiting NCT02403284 Phase 4 Liraglutide;Sugar Pill
12 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
13 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
14 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Unknown status NCT00504348 Phase 2, Phase 3 Tacrolimus
15 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
16 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
17 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
18 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
19 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
20 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
21 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
22 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
23 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
24 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
25 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
26 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
27 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
28 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
29 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
30 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
31 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
32 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
33 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
34 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Active, not recruiting NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
35 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Not yet recruiting NCT03312634 Phase 3 Palovarotene
36 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
37 Statins for the Early Treatment of Sepsis Unknown status NCT00528580 Phase 2 Simvastatin;Identical-appearing placebo
38 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
39 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
40 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
41 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
42 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
43 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
44 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
45 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
46 An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Completed NCT02190747 Phase 2 Palovarotene;Placebo
47 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
48 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
49 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
50 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

id Genetic test Affiliating Genes
1 Myositis 29

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

39
Bone, Testes, Skin, T Cells, Skeletal Muscle, Lung, Tongue

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 1970)
id Title Authors Year
1
Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis or GNE myopathy. ( 28042944 )
2017
2
Henoch-SchAPnlein Purpura With Muscle Involvement, Presenting as Myositis. ( 28002161 )
2017
3
Myositis ossificans in elbow mimicking soft tissue sarcoma: Similar clinical and radiological findings. ( 28641932 )
2017
4
Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort. ( 28864644 )
2017
5
Novel insights of disability assessment in adult myositis. ( 28796006 )
2017
6
Unsupervised Exercise-Induced Myositis Ossificans in the Brachialis Muscle of a Young Healthy Male: A Case Report. ( 28795074 )
2017
7
Myositis Ossificans of the Hip Due to Pyogenic Arthritis Caused by Campylobacter fetus Subspecies fetus. ( 28420848 )
2017
8
Focal myositis associated to radiculopathy. ( 28629659 )
2017
9
Giant cell myocarditis masquerading as orbital myositis with a rapid, fulminant course necessitating mechanical support and heart transplantation. ( 28772042 )
2017
10
Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy. ( 28111778 )
2017
11
A case of inclusion body myositis complicated by microscopic polyangiitis. ( 28726537 )
2017
12
Non-granulomatous myositis in a patient with ulcerative colitis who showed symptoms resembling gastrocnemius myalgia syndrome. ( 28132973 )
2017
13
Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. ( 28283597 )
2017
14
How can we pay the piper? Inclusion body myositis and the high price of a longer life. ( 28719726 )
2017
15
Genetics in inclusion body myositis. ( 28777108 )
2017
16
Investigating Idiopathic Inflammatory Myopathy; Initial Cross Speciality Experience with Use of the Extended Myositis Antibody Panel. ( 28567235 )
2017
17
A Systematic Review and Meta-Analysis ofA Prevalence Studies of Sporadic Inclusion Body Myositis. ( 28505979 )
2017
18
Sporadic Inclusion Body Myositis: MRI Findings and Correlation With Clinical and Functional Parameters. ( 28952813 )
2017
19
Recurrent Focal Myositis in Childhood: A Case Report and Systematic Review of the Literature. ( 28476523 )
2017
20
Association study reveals novel risk loci for sporadic inclusion body myositis. ( 28233382 )
2017
21
Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. ( 28082622 )
2017
22
Heterotopic ossification (myositis ossificans progressiva): A condition interfering with rheumatic disease. ( 28293462 )
2017
23
Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. ( 28870555 )
2017
24
Apparent diffusion coefficient (ADC) does not correlate with different serological parameters in myositis and myopathy. ( 28899124 )
2017
25
The role of p62/SQSTM1 in sporadic inclusion body myositis. ( 28159418 )
2017
26
Benign Acute Childhood Myositis During Influenza B Outbreak. ( 28795360 )
2017
27
Myositis ossificans in children: a review. ( 28275867 )
2017
28
Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis. ( 28927986 )
2017
29
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. ( 28821685 )
2017
30
Inclusion Body Myositis: A Case Presenting with Respiratory Failure and Autopsy Findings Leading to the Hypothesis of a Paraneoplastic Cause. ( 28642454 )
2017
31
Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. ( 28318044 )
2017
32
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ( 28385805 )
2017
33
Immune-array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity across the Myositis Spectrum. ( 28086002 )
2017
34
Rare case of herpes zoster ophthalmicus with orbital myositis, oculomotor nerve palsy and anterior uveitis. ( 28195080 )
2017
35
Difficult to Discern: Tuberculous Myositis with Poncet's Arthritis. ( 28821375 )
2017
36
Viral myositis in children. ( 28500193 )
2017
37
Surgical excision of symptomatic mature posttraumatic myositis ossificans: characteristics and outcomes in 32 athletes. ( 28780628 )
2017
38
Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. ( 28808260 )
2017
39
Intrathoracic tumor of the chest wall: A case of Castleman's disease mimicking myositis of the lower extremities. ( 28074445 )
2017
40
New immunoassays for anti-HMG-CoA reductase antibodies may lead to incorrect diagnosis in inflammatory myositis. ( 28826836 )
2017
41
Necrotizing streptococcal myositis of the upper extremity: a case report. ( 28807000 )
2017
42
Imaging in myositis ossificans: Bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. ( 28325501 )
2017
43
Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study. ( 28829792 )
2017
44
Traumatic myositis ossificans circumscripta (MOC). ( 28679511 )
2017
45
Cardiovascular involvement in myositis. ( 28841590 )
2017
46
Concomitant occurrence of FXTAS and clinically defined sporadic inclusion body myositis: report of two cases. ( 28857524 )
2017
47
Inclusion body myositis pathogenesis: Steady progress. ( 28318035 )
2017
48
A Case of Asymptomatic Inclusion Body Myositis. ( 28221303 )
2017
49
Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. ( 28122761 )
2017
50
Fist sign in inclusion body myositis. ( 28215761 )
2017

Variations for Myositis

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.07 APP BACE1 MAPT NCAM1
2
Show member pathways
11.7 AARS HARS NARS TARS
3 10.86 APP BACE1 MAPT
4 10.58 APP BACE1 BACE2 MAPT

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 AARS APP DYSF FBL MB NARS
2 cell surface GO:0009986 9.65 APP BACE1 BACE2 DMD NCAM1
3 Z disc GO:0030018 9.54 CAPN3 DMD TTN
4 axon GO:0030424 9.5 APP BACE1 MAPT
5 cytosol GO:0005829 9.47 AARS APP CAPN3 CHKB DMD GNE
6 astrocyte projection GO:0097449 8.65 APP

Biological processes related to Myositis according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 translation GO:0006412 9.8 AARS HARS NARS TARS
2 muscle organ development GO:0007517 9.61 CAPN3 DMD MSTN
3 response to muscle activity GO:0014850 9.48 CAPN3 MSTN
4 skeletal muscle tissue regeneration GO:0043403 9.46 DMD MSTN
5 tRNA aminoacylation GO:0043039 9.4 AARS TARS
6 beta-amyloid metabolic process GO:0050435 9.37 BACE1 BACE2
7 negative regulation of kinase activity GO:0033673 9.32 MAPT MSTN
8 amyloid fibril formation GO:1990000 9.26 APP MAPT
9 muscle cell cellular homeostasis GO:0046716 9.13 CAPN3 DMD MSTN
10 tRNA aminoacylation for protein translation GO:0006418 8.92 AARS HARS NARS TARS
11 astrocyte activation GO:0048143 8.85 MAPT

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.61 AARS CHKB GNE HARS IFIH1 NARS
2 ligase activity GO:0016874 9.56 AARS HARS NARS TARS
3 aspartic-type endopeptidase activity GO:0004190 9.37 BACE1 BACE2
4 structural constituent of muscle GO:0008307 9.33 CAPN3 DMD TTN
5 ligase activity, forming aminoacyl-tRNA and related compounds GO:0016876 9.32 AARS TARS
6 aminoacyl-tRNA ligase activity GO:0004812 8.92 AARS HARS NARS TARS

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....